Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18667713 | 0.92 | SCN9A (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL23369969 | 0.87 | AOC2 (0.37) | — | |
| SCHEMBL30870471 | 0.82 | KDM4E (0.31) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL23527820 | 0.82 | APP (0.32) | ALDH1A1 | |
| SCHEMBL21798142 | 0.81 | — | — | |
| SCHEMBL871146 | 0.80 | PRKCA (0.30) | — | |
| SCHEMBL4119407 | 0.79 | KDM4E (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4119964 | 0.78 | KDM4E (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1475092 | 0.77 | USP2 (0.41) | USP2ALDH1A1 | |
| SCHEMBL17794233 | 0.72 | KDM4E (0.37) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-07-02 | — | — | US | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | FAXIAN THERAPEUTICS, LLC | 2024-05-16 | — | — | US | disclosed |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-03-14 | — | — | US | disclosed |
| EP-3365335-B1 | 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-4288442-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | Faxian Therapeutics, LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
| EP-1703908-A4 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024503-B2 | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | JAK3, JAK1, JAK2 | KDM4E 548/4885USP2 3156/4885ALDH1A1 1199/4885 |
| US-20240158412-A1 | UBIQUITIN-SPECIFIC PROTEASE 7 (USP7) INHIBITORS AND USES THEREOF | USP7, USP28, USP1 | KDM4E 545/4885USP2 4/4885ALDH1A1 1048/4885 |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | KDM4E 3490/4885USP2 3443/4885ALDH1A1 1749/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | KDM4E 951/4885USP2 3148/4885ALDH1A1 2323/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | KDM4E 1481/4885USP2 1342/4885ALDH1A1 118/4885 |
| US-20240083882-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | KDM4E 553/4885USP2 3135/4885ALDH1A1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.